Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于获得药品注册证书的公告
Regulatory Filings Classification · 91% confidence The document is an official company announcement about receiving a drug registration certificate from the national drug regulator. It is not a financial report, management discussion, dividend notice, M&A, or other specific category. It is a general regulatory/compliance announcement, so it falls under the fallback category of Regulatory Filings (RNS).
2026-05-18 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2025年度募集资金存放和使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from Huatai United Securities regarding the special audit of the use and storage of raised funds by Xintiandi Pharmaceutical Co., Ltd. for the year 2025. It includes specific financial figures about the amount raised, usage, balance, investment projects, and compliance with regulatory requirements. The document references regulatory rules and agreements related to the management of raised funds. It is not a brief announcement or a certification letter but a comprehensive audit report on the raised funds usage and management. Therefore, it fits the category of an Audit Report / Information (AR). FY 2025
2026-03-19 Chinese
关于会计师事务所2025年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the fiscal year 2025. It discusses the audit firm's background, the procedures followed for appointment, the audit work done for the 2025 annual financial statements, and an assessment of the audit firm's performance. It includes references to audit reports, internal control audits, and compliance with accounting standards. The document is not the audit report itself but an evaluation of the audit firm's performance and the audit process for the year 2025. It is a standalone report related to audit activities but does not contain the full annual report or financial statements. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content about audit evaluation, not just an announcement or certification, so it is not RPA or RNS. Hence, the classification is AR with high confidence. FY 2025
2026-03-19 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2025, approved by the company's board meeting. It includes financial figures and accounting details but does not represent a full annual or interim financial report. It is a specific financial disclosure related to related-party transactions and fund usage, which is typically part of regulatory compliance disclosures rather than a full report like an Annual Report (10-K) or Interim Report (IR). The document is not an announcement or a brief summary but a detailed financial table. Given the nature of the content and the absence of broader financial statements or management discussion, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory disclosures that do not fit other categories.
2026-03-19 Chinese
2025年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' (Audit Report) for the fiscal year 2025 of 新天地药业股份有限公司. It contains detailed audit opinions, descriptions of audit procedures, key audit matters such as revenue recognition and fixed asset confirmation, and includes consolidated financial statements such as balance sheets, income statements, cash flow statements, and notes to the financial statements. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report prepared by an accounting firm, focusing on the audit of the company's financial statements and the auditor's opinion, rather than the full annual report or management discussion. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2025
2026-03-19 Chinese
新天地药业股份有限公司2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by an accounting firm (Grant Thornton) and addresses the effectiveness of internal control over financial reporting as of December 31, 2025. The content includes auditor responsibilities, company responsibilities, and an audit opinion on internal control effectiveness. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other type of filing. It matches the definition of an Audit Report / Information (AR). The document length is short but contains substantive audit opinion content, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2025
2026-03-19 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.